Dr. Michael Tsoukas, M.D.
Claim this profileResearch Institute of the McGill University Health Center
Studies Diabetic Retinopathy
Studies Diabetes Mellitus
4 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Michael Tsoukas, M.D. is currently running
Automated Insulin + Pramlintide Delivery
for Type 1 Diabetes
The aim of this clinical trial is to investigate whether a fully automated Lyumjev-and-pramlintide delivery system improves glycemic outcomes in adults with type 1 diabetes. The main question we aim to answer is whether a Lyumjev-pramlintide fully closed loop system improves time in range compared to a hybrid closed loop system with carbohydrate counting. We also aim to find the optimal insulin to pramlintide ratio for glycemic control in the fully automated system. In this cross-over study, patients will undergo the following three interventions in a random order: (i) fully automated Lyumjev insulin-and-pramlintide (8 μg/u) (ii) fully automated Lyumjev insulin-and-pramlintide (10 μg/u) (iii) rapid automated Lyumjev insulin-and-placebo with carbohydrate-matched boluses For all interventions, participants will be required to wear two Ypsomed pumps programmed by our developed EuGlide system.
Recruiting1 award Phase 2 & 34 criteria
Pramlintide + Insulin with Artificial Pancreas
for Type 1 Diabetes
One of the main challenges in maintaining tight glucose control in a closed-loop system occurs at meal times. Amylin is a gluco-regulatory beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli, and is deficient in patients with type 1 diabetes. Amylin, in the postprandial period, contributes to regulating glucose levels by delaying gastric emptying, suppressing nutrient-stimulated glucagon secretion, and increasing satiety. Pramlintide is a synthetic analog of the hormone amylin. A closed-loop system that delivers both insulin and pramlintide, based on glucose sensor readings, has the potential to better normalize glucose levels, especially during the post-prandial period. The aim of this project is to assess whether co-administration of pramlintide with rapid insulin in an artificial pancreas system will improve glycemic control in adults with Type 1 Diabetes.
Recruiting0 awards N/A6 criteria
More about Michael Tsoukas, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael Tsoukas, M.D. has experience with
- Artificial Pancreas
- Fully Automated Insulin And Pramlintide Delivery System
- Semaglutide
- Aspart
- Fiasp
- Pramlintide
Breakdown of trials Michael Tsoukas, M.D. has run
Diabetic Retinopathy
Diabetes Mellitus
Type 1 Diabetes
Postprandial Hyperglycemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Tsoukas, M.D. specialize in?
Michael Tsoukas, M.D. focuses on Diabetic Retinopathy and Diabetes Mellitus. In particular, much of their work with Diabetic Retinopathy has involved treating patients, or patients who are undergoing treatment.
Is Michael Tsoukas, M.D. currently recruiting for clinical trials?
Yes, Michael Tsoukas, M.D. is currently recruiting for 2 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Michael Tsoukas, M.D. has studied deeply?
Yes, Michael Tsoukas, M.D. has studied treatments such as Artificial Pancreas, Fully Automated Insulin and Pramlintide Delivery System, Semaglutide.
What is the best way to schedule an appointment with Michael Tsoukas, M.D.?
Apply for one of the trials that Michael Tsoukas, M.D. is conducting.
What is the office address of Michael Tsoukas, M.D.?
The office of Michael Tsoukas, M.D. is located at: Research Institute of the McGill University Health Center, Montreal, Quebec H4A 3T2 Canada. This is the address for their practice at the Research Institute of the McGill University Health Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.